Drug Profile
VI 1121
Alternative Names: VI-1121Latest Information Update: 10 Dec 2021
Price :
$50
*
At a glance
- Originator VIVUS
- Class Antidementias
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 31 Aug 2015 Discontinued - Phase-II for Alzheimer's disease (Adjunctive treatment) in USA (unspecified route)
- 31 Aug 2013 VIVUS completes a phase II trial for Alzheimer's disease (adjunctive treatment) in USA (NCT01428362)
- 05 Mar 2013 VIVUS completes enrolment in its phase II trial for Alzheimer's disease (adjunctive treatment) in USA (NCT01428362)